Clinical Trials › NCT05156281

Active, Not RecruitingPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsored by Novartis Pharmaceuticals

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
1011
Target enrollment
23
U.S. states
Dec 2021
Start date
Oct 2030
Expected completion
Interventions / Treatments
RemibrutinibTeriflunomide
Conditions studied
Relapsing Multiple Sclerosis
Where this trial is running (51 sites)
Florida13 sites
Bradenton · Gainesville · Hollywood · +10 more
Texas7 sites
Dallas · El Paso · Frisco · +4 more
California3 sites
Hanford · Los Angeles · West Hollywood
Colorado2 sites
Aurora · Denver
District of Columbia2 sites
Washington D.C. · Washington D.C.
New York2 sites
Patchogue · Port Jefferson
North Carolina2 sites
Chapel Hill · Charlotte
Ohio2 sites
Columbus · Dayton
South Carolina2 sites
Greenville · Old Point Station
Washington2 sites
Seattle · Seattle
Wisconsin2 sites
Milwaukee · Milwaukee
Arizona1 site
Phoenix
Connecticut1 site
Stamford
Indiana1 site
Merrillville
Kansas1 site
Kansas City
Kentucky1 site
Nicholasville
Louisiana1 site
New Orleans
Maryland1 site
Frederick
Massachusetts1 site
Boston
Missouri1 site
Kansas City
Pennsylvania1 site
Hershey
Tennessee1 site
Knoxville
West Virginia1 site
Crab Orchard
Participating MS centers on MS Buddy (31)
True North Neurology
Port Jefferson Station, NY
Premier Neurology, PC
Greenville, SC
MS centers in Florida

Compare treatment centers near a trial site — patient experience, providers, and care ratings.

View Florida centers
More Phase 3 trials
Browse all Phase 3 MS trials

Check out the MS Buddy App

Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.

Download on the App StoreGet it on Google Play